Completed PHASE3 INTERVENTIONAL 2-arm NCT00519285

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer (VENICE)

A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer

Sponsor: Regeneron Pharmaceuticals

Conditions Neoplasm Metastasis Prostatic Neoplasms

Interventions Aflibercept Docetaxel Placebo (for aflibercept) Prednisone or Prednisolone

Updated 8 times since 2017 Last updated: Jun 21, 2016 Started: Aug 31, 2007 Primary completion: Apr 30, 2012 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Neoplasm Metastasis and Prostatic Neoplasms and is currently completed. Regeneron Pharmaceuticals leads this study, which shows 8 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Regeneron Pharmaceuticals
Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Bridgewater, United States , Bromma, Sweden , Budapest, Hungary , Buenos Aires, Argentina , City of Zagreb, Croatia , Diegem, Belgium , Frankfurt, Germany , Gauteng, South Africa , Geneva, Switzerland and 21 more locations